TACE With Thermosensitive Nanogel Versus Embosphere for HCC
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
Trial Details
- NCT ID
- NCT06593964
- Phase
- NA
- Sponsor
- Zhongda Hospital
- Status
- RECRUITING
- Cancer Type
- Liver Cancer
- Interventions
- Thermosensitive Nanogel Embolic Agent
- Locations (sample)
- Nanjing, China|32.06167,118.77778
Key Eligibility Criteria
- Chinese Liver Cancer Staging Scheme, stage IIb-Illa, as well as those with stage Ia-Ila HCC, unsuitable or unwilling to undergo surgical resection,…
- Liver function status: Child-Pugh A or B
- Eastern Cooperative Oncology Group score: 0-2 points;
- With at least one measurable, unembolized liver tumor lesion (1-10 cm) ;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Liver Cancer Trials on Trialify →